Abstract: The present invention relates to therapeutically active compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.
Type:
Grant
Filed:
June 1, 1998
Date of Patent:
June 13, 2000
Assignees:
Novo Nordisk, Karo Bio AB
Inventors:
Anker Steen Jorgensen, Poul Jacobsen, Lise Brown Christiansen, Paul Stanley Bury, Anders Kanstrup
Abstract: This invention relates to a novel estrogen receptor-related nuclear receptor, hereinafter termed "ER.beta." having the amino acid sequence of FIGS. 1, 13A or 14A or substantially the same ambino acid sequence as the amino acid sequence shown in FIGS. 1, 13A or 13B or an amino acid sequence functionally similar to that sequence. The invention also relates to DNA sequences encoding the receptor. The receptor may be useful in isolating molecules for the treatment of disorders such as prostate cancer, benign prostatic hyperplasia, osteoporosis or cardiovascular disorders and in the testing of substances for estrogenic and other hormonal effects.
Type:
Grant
Filed:
May 8, 1997
Date of Patent:
September 28, 1999
Assignee:
Karo Bio AB
Inventors:
Georg Kuiper, Eva L. K. Enmark, Jan-Ake Gustafsson
Abstract: The invention provides compounds according to the formula ##STR1## in which: Ha=I or BrX=CH.sub.2 or C=OR.sup.1 =C.sub.1-4 alkylR.sup.2 =--NHSO.sub.2 R.sup.3 ;--NHCOR.sup.3 ; or--NHCONHR.sup.3where R.sup.3 =--CF.sub.3,C.sub.1-3 alkyl, 4-R.sup.4 C.sub.6 H.sub.4 --;where R.sup.4 =C.sub.1-4 alkoxy-; hydroxy-; fluoro-; or nitro-;or a pharmaceutically acceptable salt thereof.The compounds may particularly be used in the treatment of T3 regulated gene disorders and diseases.